drugset / Trial / NCT02560441

Summary

The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both arms are 3 cycles. And the chemotherapy is repeated every 3 weeks.. The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is repeated every 3 weeks.

Timeline

Start
2015-09
Primary completion
2022-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg Intravenous
Subject Dexamethasone Small molecule 20 mg Intravenous
Subject Gemcitabine Small molecule 800 mg Intravenous
Subject Ifosfamide Small molecule 1.2 g Intravenous
Subject Pegaspargase Protein / enzyme biologic 2000 iu Intramuscular